Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany.
Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany.
Talanta. 2019 Nov 1;204:386-394. doi: 10.1016/j.talanta.2019.06.004. Epub 2019 Jun 3.
The determination of endocannabinoids and endocannabinoid-like substances in biological human samples is a vibrant field of research with great significance due to postulated relevance of these substances in diseases such as Alzheimer's disease, multiple sclerosis, cancer and cardiovascular diseases. For a possible use as biomarker in early prediction or diagnosis of a disease as well as examination of a successful treatment, the valid determination of the analytes in common accessible human samples, such as plasma or serum, is of great importance. A method for the determination of arachidonoyl ethanolamide, oleoyl ethanolamide, palmitoyl ethanolamide, 1-arachidonoyl glycerol and 2-arachidonoyl glycerol in human K3EDTA plasma using liquid-liquid-extraction in combination with liquid chromatography-tandem-mass spectrometry has been developed and validated for the quantification of the aforementioned analytes. Particular emphasis was placed on the chromatographic separation of the isomers 1-arachidonoyl glycerol and 2-arachidonoyl glycerol, arachidonoyl ethanolamide and O-arachidonoyl ethanolamine (virodhamine) as well as oleoyl ethanolamide and vaccenic acid ethanolamide. During the validation process, increasing concentrations of 1-arachidonoyl glycerol and 2-arachidonoyl glycerol while storing plasma samples were observed. In-depth investigation of pre-analytical sample handling revealed rising concentrations for both analytes in plasma and for arachidonoyl ethanolamide, oleoyl ethanolamide and palmitoyl ethanolamide in whole blood, dependent on the period and temperature of storage. Prevention of the increase in concentration was not possible, raising the question whether human K3EDTA plasma is suitable for the determination of endocannabinoids and endocannabinoid-like substances. Especially the common practice to calculate the concentration of 2-arachidonoyl glycerol as sum of 1-arachidonoyl glycerol and 2-arachidonoyl glycerol is highly questionable because the concentrations of both analytes increase unequally while storing the plasma samples in the fridge.
内源性大麻素和内源性大麻素样物质在生物人体样本中的测定是一个充满活力的研究领域,具有重要意义,因为这些物质在阿尔茨海默病、多发性硬化症、癌症和心血管疾病等疾病中被假定具有相关性。为了在疾病的早期预测或诊断中以及在检查治疗的成功与否时可能将这些物质用作生物标志物,在常见的可获得的人体样本(如血浆或血清)中有效测定分析物非常重要。本文建立并验证了一种使用液液萃取结合液相色谱-串联质谱法测定人 K3EDTA 血浆中花生四烯酰乙醇胺、油酰乙醇胺、棕榈酰乙醇胺、1-花生四烯酰甘油和 2-花生四烯酰甘油的方法,用于定量分析上述分析物。特别强调了异构体 1-花生四烯酰甘油和 2-花生四烯酰甘油、花生四烯酰乙醇胺和 O-花生四烯酰乙醇胺(育亨宾)以及油酰乙醇胺和大麻酸乙醇胺的色谱分离。在验证过程中,观察到在储存血浆样品时,1-花生四烯酰甘油和 2-花生四烯酰甘油的浓度不断增加。对样本前处理的深入调查显示,两种分析物在血浆中的浓度以及在全血中的花生四烯酰乙醇胺、油酰乙醇胺和棕榈酰乙醇胺的浓度均升高,这取决于储存时间和温度。无法防止浓度增加,这引发了一个问题,即人 K3EDTA 血浆是否适合测定内源性大麻素和内源性大麻素样物质。特别是将 2-花生四烯酰甘油的浓度计算为 1-花生四烯酰甘油和 2-花生四烯酰甘油的总和的常见做法非常值得怀疑,因为在将血浆样本储存在冰箱中时,两种分析物的浓度增加并不均匀。